Xeltis proprietary ETR technology harnesses the body’s natural healing processes, enabling the development of functional, living new vessels and heart valves that grow and remodel over time. Xeltis develops groundbreaking implants that facilitate the natural formation of living, durable vessels, addressing substantial unmet needs for millions of patients requiring vascular therapy. The relevant markets, such as end-stage kidney disease (dialysis) (aXess), coronary disease (Xabg), and peripheral arterial disease (Xpad), are collectively worth over USD 10 billion.

Xeltis' flagship device aXess, is a polymeric implant that is gradually replaced by the patient’s own healthy new tissue is in advanced clinical trials both in EU and US.